120 related articles for article (PubMed ID: 9920539)
1. Impact of baseline cysts at the time of administration of gonadotropin-releasing hormone analog for in vitro fertilization.
Zeyneloglu HB; Isik AZ; Kara S; Senöz S; Ozcan U; Gökmen O
Int J Fertil Womens Med; 1998; 43(6):300-5. PubMed ID: 9920539
[TBL] [Abstract][Full Text] [Related]
2. Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates.
Biljan MM; Mahutte NG; Dean N; Hemmings R; Bissonnette F; Tan SL
Fertil Steril; 1998 Dec; 70(6):1063-9. PubMed ID: 9848296
[TBL] [Abstract][Full Text] [Related]
3. Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol for patients with a history of poor in vitro fertilization outcomes.
Weitzman VN; Engmann L; DiLuigi A; Maier D; Nulsen J; Benadiva C
Fertil Steril; 2009 Jul; 92(1):226-30. PubMed ID: 18675961
[TBL] [Abstract][Full Text] [Related]
4. Comparative study on the pregnancy outcomes of in vitro fertilization-embryo transfer between long-acting gonadotropin-releasing hormone agonist combined with transvaginal ultrasound-guided cyst aspiration and long-acting gonadotropin-releasing hormone agonist alone.
Guo YH; Lu N; Zhang Y; Su YC; Wang Y; Zhang YL; Sun YP
Contemp Clin Trials; 2012 Nov; 33(6):1206-10. PubMed ID: 22820320
[TBL] [Abstract][Full Text] [Related]
5. Baseline cyst formation after luteal phase gonadotropin-releasing hormone agonist administration is linked to poor in vitro fertilization outcome.
Keltz MD; Jones EE; Duleba AJ; Polcz T; Kennedy K; Olive DL
Fertil Steril; 1995 Sep; 64(3):568-72. PubMed ID: 7641912
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment with an oral contraceptive is effective in reducing the incidence of functional ovarian cyst formation during pituitary suppression by gonadotropin-releasing hormone analogues.
Biljan MM; Mahutte NG; Dean N; Hemmings R; Bissonnette F; Tan SL
J Assist Reprod Genet; 1998 Nov; 15(10):599-604. PubMed ID: 9866068
[TBL] [Abstract][Full Text] [Related]
7. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
[TBL] [Abstract][Full Text] [Related]
8. In vitro fertilization cycle outcome after coasting in gonadotropin-releasing hormone (GnRH) agonist versus GnRH antagonist protocols.
Farhi J; Ben-Haroush A; Lande Y; Sapir O; Pinkas H; Fisch B
Fertil Steril; 2009 Feb; 91(2):377-82. PubMed ID: 18321490
[TBL] [Abstract][Full Text] [Related]
9. Does prolonged pituitary down-regulation with gonadotropin-releasing hormone agonist improve the live-birth rate in in vitro fertilization treatment?
Ren J; Sha A; Han D; Li P; Geng J; Ma C
Fertil Steril; 2014 Jul; 102(1):75-81. PubMed ID: 24746740
[TBL] [Abstract][Full Text] [Related]
10. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
[TBL] [Abstract][Full Text] [Related]
11. Ovarian cyst formation following GnRH agonist administration in IVF cycles: incidence and impact.
Qublan HS; Amarin Z; Tahat YA; Smadi AZ; Kilani M
Hum Reprod; 2006 Mar; 21(3):640-4. PubMed ID: 16253965
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle].
Yang S; Chen XN; Qiao J; Liu P; Li R; Chen GA; Ma CH
Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):245-9. PubMed ID: 22781108
[TBL] [Abstract][Full Text] [Related]
13. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
14. Selection of first in vitro fertilization cycle stimulation protocol for good prognosis patients: gonadotropin releasing hormone antagonist versus agonist protocols.
Johnston-MacAnanny EB; DiLuigi AJ; Engmann LL; Maier DB; Benadiva CA; Nulsen JC
J Reprod Med; 2011; 56(1-2):12-6. PubMed ID: 21366121
[TBL] [Abstract][Full Text] [Related]
15. Follicle cysts after menstrual versus midluteal administration of gonadotropin-releasing hormone analog in in vitro fertilization.
Herman A; Ron-El R; Golan A; Nahum H; Soffer Y; Caspi E
Fertil Steril; 1990 May; 53(5):854-8. PubMed ID: 2185043
[TBL] [Abstract][Full Text] [Related]
16. [Correlation between serum inhibin B level after treatment with gonadotropin releasing hormone agonist and outcome of in vitro fertilization-embryo transfer].
Lin WQ; Yang HY; Lin JJ; Chen X; Ye BL
Zhonghua Fu Chan Ke Za Zhi; 2009 Apr; 44(4):260-2. PubMed ID: 19570462
[TBL] [Abstract][Full Text] [Related]
17. Treatment outcome in women with a single ovary versus patients with two ovaries undergoing in vitro fertilization and embryo transfer (IVF/ET).
Levitas E; Furman B; Shoham-Vardi I; Lunenfeld E; Potashnik G
Eur J Obstet Gynecol Reprod Biol; 2000 Feb; 88(2):197-200. PubMed ID: 10690680
[TBL] [Abstract][Full Text] [Related]
18. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
Hohmann FP; Macklon NS; Fauser BC
J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
[TBL] [Abstract][Full Text] [Related]
19. The effects of baseline ovarian cysts on the clinical response to controlled ovarian hyperstimulation in an in vitro fertilization program.
Hornstein MD; Barbieri RL; Ravnikar VA; McShane PM
Fertil Steril; 1989 Sep; 52(3):437-40. PubMed ID: 2673843
[TBL] [Abstract][Full Text] [Related]
20. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
